A Study of LY900014 and Insulin Degludec in Participants With Type 1 Diabetes

Completed · Phase 2

Conditions studied: Type 1 Diabetes

In brief

In this study, participants with type 1 diabetes (T1D) will take the study drug LY900014 and insulin degludec. The reason for this study is to evaluate the amount of time with glucose values within target range.

Key facts

Study ID

NCT04585776

Run by

Eli Lilly and Company

People needed

31

Starts

2020-10-30

Expected to finish

2021-05-27

Last updated by the study team

2022-06-03

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants must have type 1 diabetes and have been treated with insulin therapy for at least 1 year
• Participants must be using Continuous Glucose Monitoring (CGM) with total CGM use ≥ 2 months in the prior 6 months
• Participants must have been on the same type of short acting insulin (Humalog U-100, Novolog, Admelog, or Apidra) for at least 30 days prior to screening
• Participants must have been treated with long-acting insulin degludec U-100 for at least 30 days prior to screening

You may not qualify if…

• Participants must not have had more than 1 emergency room visit or hospitalization due to poor glucose control within 6 months before screening
• Participants must not have had more than 1 episode of severe hypoglycemia within the last 90 days prior to screening
• Participants must not be taking certain diabetes medications that are not allowed for study participation

Where it is running

• Atlanta Diabetes Associates — Atlanta, Georgia, United States
• Iowa Diabetes and Endocrinology Research Center — West Des Moines, Iowa, United States
• HealthPartners Institute dba International Diabetes Center — Minneapolis, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.